A ruling by the European Court of Justice is fueling the debate about a reform of competition law. The Luxembourg judges annulled the EU Commission’s decision to prohibit the US medical technology manufacturer Illumina from taking over Grail. The EU competition authorities should not have examined the deal because the start-up Grail did not meet the European or national thresholds. The judges justified their decision by stating that companies need planning and legal certainty for such transactions.